UK markets closed

Zoetis Inc. (0M3Q.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
165.25+0.62 (+0.38%)
At close: 06:23PM GMT

Zoetis Inc.

10 Sylvan Way
Parsippany, NJ 07054
United States
973 822 7000

Full-time employees13,800

Key executives

NameTitlePayExercisedYear born
Ms. Kristin C. PeckCEO & Director3.86M7.64M1971
Mr. Wetteny N. JosephExec. VP & CFO2.91MN/A1972
Ms. Heidi C. ChenExec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics1.39M5.56M1967
Ms. Roxanne LaganoExec. VP and Chief HR Officer & Global OperationsN/AN/A1965
Ms. Wafaa MamilliEVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal HealthN/AN/A1968
Mr. Steven FrankVP of Investor RelationsN/AN/AN/A
Mr. William PriceVP & Chief Communications OfficerN/AN/AN/A
Dr. Robert J. Polzer Ph.D.Exec. VP and Pres of R&DN/AN/A1969
Ms. Jeannette Ferran AstorgaExec. VP of Corp. Affairs & Communications and Chief Sustainability OfficerN/AN/A1975
Mr. Nick AshtonExec. VP and Pres of Global Manufacturing & SupplyN/AN/A1973
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides testing and analysis of blood, urine, and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Corporate governance

Zoetis Inc.’s ISS governance QualityScore as of 1 March 2023 is 2. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.